Lead Product(s): TCRT-ESO-A2
Therapeutic Area: Oncology Product Name: TCRT-ESO-A2
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 13, 2020
Axis Therapeutics and PharmaEssentia will collaborate to conduct an initial clinical study of Axis Therapeutics’ TCRT-ESO-A2 therapy, targeting solid tumors that are NY-ESO-1 positive in HLA-A positive patients, and to manufacture the investigational products, in Taiwan.
Lead Product(s): SACT-1
Therapeutic Area: Oncology Product Name: SACT-1
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 02, 2020
Aptorum Group intends to use the net proceeds to conduct further analyses of SACT-1 and ALS-4, currently on track for IND submission to commence Phase 1b/2a clinical trials and undergoing final stages of IND enabling studies for Phase 1 human clinical trials respectively.